PRKDC Mutation

CI-VAR-00002802Explore in graph →CIViC 4860

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Diffuse Large B-Cell Lymphoma1
PRKDC Mutation	(oncogenic)	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11979 This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes PMID 29641966 · Schmitz et al., 2018 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
PRKDC Mutation	Anti-CTLA-4 Monoclonal Antibody + Anti-PD1 Monoclonal AntibodyCombination	Predictive	B	Supports Sensitivity Response	2	accepted	EID13225 In a retrospective analysis of the Hellmann cohort of 75 patients with non-small cell lung cancer treated with combined PD-1 and CTLA-4 blockade, 6 patients with nonsynonymous PRKDC mutations had a hi…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
PRKDC Mutation	Anti-CTLA-4 Monoclonal Antibody	Predictive	B	Supports Sensitivity Response	2	accepted	EID13226 In a retrospective analysis of the Allen cohort of 110 patients with advanced melanoma treated with CTLA-4 blockade, 9 patients with nonsynonymous PRKDC mutations had a higher objective response rate … (full text at CIViC) PMID 32502294 · Chen et al., 2020 · Open in CIViC	civic